# Intranasal Oxytocin in Hypothalamic Obesity

> **NCT02849743** · PHASE2 · COMPLETED · sponsor: **Shana McCormack, MD** · enrollment: 18 (actual)

## Conditions studied

- Craniopharyngioma
- Hypothalamic Obesity

## Interventions

- **DRUG:** Syntocinon
- **DRUG:** Placebo (for Syntocinon)

## Key facts

- **NCT ID:** NCT02849743
- **Lead sponsor:** Shana McCormack, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10
- **Primary completion:** 2021-04
- **Final completion:** 2022-05
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2022-10-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02849743

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02849743, "Intranasal Oxytocin in Hypothalamic Obesity". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02849743. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*